Ribociclib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-RIBOCICLIB |
|---|---|
| Type | Drug |
| Aliases | KisqaliРибоцикліб |
| Status | pending_clinical_signoff |
| Diseases | DIS-BREAST |
| Sources | SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Drug Facts
| Class | CDK4/6 inhibitor |
|---|---|
| Mechanism | CDK4/6 inhibitor with established OS benefit in metastatic HR+/HER2- (MONALEESA-2/3/7) AND adjuvant high-risk early breast (NATALEE). |
| Typical dosing | Metastatic: 600 mg PO once daily, days 1-21 of 28-day cycle. Adjuvant (NATALEE): 400 mg PO once daily, same schedule, for 3 years. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Best OS data among CDK4/6i in metastatic. NATALEE trial established 3-year adjuvant role for high-risk N+ HR+/HER2- early breast — potential standard-of-care shift.
Used By
Regimens
REG-AI-RIBOCICLIB- AI + ribociclib (HR+/HER2- metastatic 1L; OS-validated)REG-RIBOCICLIB-AI-ADJUVANT- Ribociclib adjuvant + AI (HR+/HER2- early breast cancer; NATALEE)